niacin has been researched along with Non-alcoholic Fatty Liver Disease in 9 studies
Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.
Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION.
Excerpt | Relevance | Reference |
---|---|---|
"NAFLD was defined using the United States fatty liver index (US-FLI)." | 5.91 | Association between Dietary Niacin Intake and Nonalcoholic Fatty Liver Disease: NHANES 2003-2018. ( Hu, Y; Pan, J; Pang, N; Yang, L, 2023) |
"Non-alcoholic fatty liver disease (NAFLD) is a common disorder characterized by excessive hepatic fat accumulation, production of reactive oxygen species (ROS), inflammation and potentially resulting in non-alcoholic steatohepatitis (NASH), cirrhosis and end-stage liver disease." | 5.42 | Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease. ( Ganji, SH; Kamanna, VS; Kashyap, ML, 2015) |
"Niacin treatment to rats with preexisting hepatic steatosis induced by the HF diet significantly regressed steatosis." | 5.40 | Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease. ( Ganji, SH; Kamanna, VS; Kashyap, ML; Kukes, GD; Lambrecht, N, 2014) |
"NAFLD was defined using the United States fatty liver index (US-FLI)." | 1.91 | Association between Dietary Niacin Intake and Nonalcoholic Fatty Liver Disease: NHANES 2003-2018. ( Hu, Y; Pan, J; Pang, N; Yang, L, 2023) |
"Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the world." | 1.56 | Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet. ( Cao, Z; Lai, X; Shi, Y; Ye, L; Zhou, N, 2020) |
"Niacin treatment was started from week 5 until the end of the study." | 1.56 | Niacin increases diet-induced hepatic steatosis in B6129 mice. ( Fang, H; Graff, EC; Judd, RL; Li, Z; McCafferty, KJ, 2020) |
"Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder in industrialized countries, yet its pathophysiology is incompletely understood." | 1.42 | Metabolomic tissue signature in human non-alcoholic fatty liver disease identifies protective candidate metabolites. ( Becker, T; Beldi, G; Brosch, M; Brückner, S; Erhart, W; Fahrner, R; Gruodyte, A; Hampe, J; Hinrichsen, H; Itzel, T; Landrock, A; Patsenker, E; Richter, K; Röcken, C; Schafmayer, C; Schreiber, S; Sipos, B; Stickel, F; Teufel, A; Vollnberg, B; von Schönfels, W, 2015) |
"Non-Alcoholic Fatty Liver Disease (NAFLD) is a common liver disorder, characterized by an excessive lipids deposition within the hepatic tissue." | 1.42 | Raman spectroscopy analysis of lipid droplets content, distribution and saturation level in Non-Alcoholic Fatty Liver Disease in mice. ( Baranska, M; Chlopicki, S; Kochan, K; Kostogrys, R; Krafft, C; Maslak, E, 2015) |
"Non-alcoholic fatty liver disease (NAFLD) is a common disorder characterized by excessive hepatic fat accumulation, production of reactive oxygen species (ROS), inflammation and potentially resulting in non-alcoholic steatohepatitis (NASH), cirrhosis and end-stage liver disease." | 1.42 | Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease. ( Ganji, SH; Kamanna, VS; Kashyap, ML, 2015) |
"Niacin treatment to rats with preexisting hepatic steatosis induced by the HF diet significantly regressed steatosis." | 1.40 | Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease. ( Ganji, SH; Kamanna, VS; Kashyap, ML; Kukes, GD; Lambrecht, N, 2014) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (55.56) | 24.3611 |
2020's | 4 (44.44) | 2.80 |
Authors | Studies |
---|---|
Cardoso-Lezama, I | 1 |
Fuentes-Figueroa, MÁ | 1 |
Ramos-Tovar, E | 1 |
Márquez-Quiroga, LV | 1 |
Ortiz-Fernández, A | 1 |
Vargas-Pozada, EE | 1 |
Arellanes-Robledo, J | 1 |
Tsutsumi, V | 1 |
Muriel, P | 1 |
Pan, J | 1 |
Hu, Y | 1 |
Pang, N | 1 |
Yang, L | 1 |
Ye, L | 1 |
Cao, Z | 1 |
Lai, X | 1 |
Shi, Y | 1 |
Zhou, N | 1 |
Fang, H | 1 |
Li, Z | 1 |
Graff, EC | 1 |
McCafferty, KJ | 1 |
Judd, RL | 1 |
Ganji, SH | 2 |
Kukes, GD | 1 |
Lambrecht, N | 1 |
Kashyap, ML | 2 |
Kamanna, VS | 2 |
van den Hoek, AM | 1 |
van der Hoorn, JW | 1 |
Maas, AC | 1 |
van den Hoogen, RM | 1 |
van Nieuwkoop, A | 1 |
Droog, S | 1 |
Offerman, EH | 1 |
Pieterman, EJ | 1 |
Havekes, LM | 1 |
Princen, HM | 1 |
von Schönfels, W | 1 |
Patsenker, E | 1 |
Fahrner, R | 1 |
Itzel, T | 1 |
Hinrichsen, H | 1 |
Brosch, M | 1 |
Erhart, W | 1 |
Gruodyte, A | 1 |
Vollnberg, B | 1 |
Richter, K | 1 |
Landrock, A | 1 |
Schreiber, S | 1 |
Brückner, S | 1 |
Beldi, G | 1 |
Sipos, B | 1 |
Becker, T | 1 |
Röcken, C | 1 |
Teufel, A | 1 |
Stickel, F | 1 |
Schafmayer, C | 1 |
Hampe, J | 1 |
Kochan, K | 1 |
Maslak, E | 1 |
Krafft, C | 1 |
Kostogrys, R | 1 |
Chlopicki, S | 1 |
Baranska, M | 1 |
9 other studies available for niacin and Non-alcoholic Fatty Liver Disease
Article | Year |
---|---|
Nicotinic acid attenuates experimental non-alcoholic steatohepatitis by inhibiting the NLRP3 inflammasome/pyroptosis pathway.
Topics: Animals; Humans; Inflammasomes; Mice; Mice, Inbred C57BL; Niacin; NLR Family, Pyrin Domain-Containin | 2023 |
Association between Dietary Niacin Intake and Nonalcoholic Fatty Liver Disease: NHANES 2003-2018.
Topics: Diet; Humans; Niacin; Non-alcoholic Fatty Liver Disease; Nutrition Surveys; Nutritional Status; Unit | 2023 |
Niacin Ameliorates Hepatic Steatosis by Inhibiting De Novo Lipogenesis Via a GPR109A-Mediated PKC-ERK1/2-AMPK Signaling Pathway in C57BL/6 Mice Fed a High-Fat Diet.
Topics: Adenylate Kinase; Animals; Diet, High-Fat; Gene Knockdown Techniques; Hep G2 Cells; Humans; Lipogene | 2020 |
Niacin increases diet-induced hepatic steatosis in B6129 mice.
Topics: Animals; Diet, High-Fat; Hypolipidemic Agents; Insulin Resistance; Lipid Metabolism; Lipoproteins, V | 2020 |
Therapeutic role of niacin in the prevention and regression of hepatic steatosis in rat model of nonalcoholic fatty liver disease.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Disease Models, Animal; Disease Progression; Fatty | 2014 |
APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Apolipoprotein E3; Atorvastatin; Cholesterol E | 2014 |
Metabolomic tissue signature in human non-alcoholic fatty liver disease identifies protective candidate metabolites.
Topics: Animals; Biopsy; Dietary Supplements; Gas Chromatography-Mass Spectrometry; Humans; Hydroquinones; L | 2015 |
Raman spectroscopy analysis of lipid droplets content, distribution and saturation level in Non-Alcoholic Fatty Liver Disease in mice.
Topics: Animals; Apolipoproteins E; Diet, High-Fat; Dietary Carbohydrates; Dietary Proteins; Lipid Droplets; | 2015 |
Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease.
Topics: Diacylglycerol O-Acyltransferase; Hepatocytes; Humans; Hypolipidemic Agents; Interleukin-8; Lipid Me | 2015 |